natgillin/translations-raw huggingface dataset:
Virkningen af flere doser glycerolphenylbutyrat 13,2 g/dag og 19,8 g/dag (cirka 69 % og 104 % af den maksimale anbefalede daglige dosis) på QTc-intervallet blev evalueret hos 57 raske forsøgspersoner i et randomiseret placebo- og aktivt kontrolleret (moxifloxacin 400 mg) overkrydsningsstudier med fire behandlingsgrupper. 
The effect of multiple doses of glycerol phenylbutyrate 13.2 g/day and 19.8 g/day (approximately 69% and 104% of the maximum recommended daily dosage) on QTc interval was evaluated in a randomised, placebo- and active-controlled (moxifloxacin 400 mg), four-treatment-arm, crossover study in 57 healthy subjects.
RAVICTI kan i væsentlig grad påvirke evnen til at føre motorkøretøj og betjene maskiner, da behandling med glycerolphenylbutyrat kan forårsage svimmelhed eller hovedpine (se pkt. 
RAVICTI may have major influence on the ability to drive and use machines given that treatment with glycerol phenylbutyrate may cause dizziness or headaches (see section 4.8).
Forligelighedsstudier har påvist, at glycerolphenylbutyrat er kemisk og fysisk stabilt under anvendelse med følgende fødevarer og kosttilskud: æblemos, ketchup, græskarmos og fem ernæringspræparater (Cyclinex-1, Cyclinex-2, UCD-1, UCD-2, Polycose , Pro Phree og citrullin), som typisk bruges af UCD-patienter (se pkt. 
Compatibility studies have demonstrated glycerol phenylbutyrate chemical and physical in-use stability with the following foods and nutritional supplements: apple sauce, ketchup, squash puree, and five medical formulas (Cyclinex-1, Cyclinex-2, UCD-1, UCD-2, Polycose, Pro Phree and Citrulline) typically consumed by UCD patients (see section 4.2).
Ikke almindelig Hypotyroidisme 
Uncommon Hypothyroidism
Hos raske forsøgspersoner steg den systemiske eksponering for PAA, PBA og PAGN dosisafhængigt. 
In healthy subjects, the systemic exposure to PAA, PBA, and PAGN increased in a dose dependent manner.
Den gennemsnitlige ratio mellem peak af PAA og peak af PAGN hos UCD-patienter fra fødslen til under 2 måneder var højere (gennemsnit: 1,65, interval 0,14-7,07) end hos UCD-patienter i alderen 2 måneder til under 2 år (gennemsnit 0,59, interval 0,17-1,21). 
The mean peak ratio of PAA to PAGN in UCD patients aged birth to less than 2 months was higher (mean: 1.65; range 0.14 to 7.07) than for UCD patients aged 2 months to less than 2 years (mean 0.59; range 0.17 to 1.21).
Hvis symptomerne opkastning, kvalme, hovedpine, døsighed, forvirring eller søvnløshed er til stede uden et højt ammoniakniveau eller andre interkurrente sygdomme, skal plasma-PAA og plasmaPAA:PAGN-ratio måles, og det skal overvejes at reducere dosis af glycerolphenylbutyrat eller øge doseringshyppigheden, hvis PAA-niveauet overstiger 500 mikrogram/l, og plasma-PAA:PAGNratioen overstiger 2,5. 
If symptoms of vomiting, nausea, headache, somnolence, confusion, or sleepiness are present in the absence of high ammonia or other intercurrent illnesses, measure plasma PAA and plasma PAA to PAGN and consider reduction of glycerol phenylbutyrate dosage or increase the frequency of dosing if the PAA level exceeds 500 mcg/L and the plasma PAA to PAGN ratio exceeds 2.5.
Populationsfarmakokinetisk modellering og dosissimuleringer antyder, at PBA optages i kredsløbet ca. 70-75 % langsommere, når det gives oralt som glycerolphenylbutyrat sammenlignet med natriumphenylbutyrat, og indikerer endvidere, at kropoverfladearealet er den mest signifikante kovariat til at forklare variabiliteten i PAA-clearance. 
Population pharmacokinetic modelling and dosing simulations suggest that PBA enters the circulation about 70-75% more slowly when given orally as glycerol phenylbutyrate as compared with sodium phenylbutyrate and further indicate that body surface area is the most significant covariate explaining the variability of PAA clearance.
• døsighed, træthed, uklarhed eller undertiden forvirring 
• feeling sleepy, tired, light-headed or sometimes confused
Det er vist, at glycerolphenylbutyrat og/eller dets metabolitter, PAA og PBA er svage CYP3A4induktorer in vivo. 
Glycerol phenylbutyrate and/or its metabolites, PAA and PBA, have been shown to be weak inducers of CYP3A4 enzyme in vivo.
Da PAA omdannes til PAGN i leveren, kan patienter med svært nedsat leverfunktion have en reduceret konverteringsevne og højere plasma-PAA og plasma-PAA:PAGN-ratio. 
Because conversion of PAA to PAGN occurs in the liver, patients with severe hepatic impairment may have reduced conversion capability and higher plasma PAA and plasma PAA to PAGN ratio.
Den samme sprøjte skal bruges til alle doser samme dag. 
The same oral syringe should be used for all doses taken each day.
Det anbefales ikke at administrere en dosis på 0,5 ml eller derunder med en nasogastrisk, nasojejunal eller gastrostomisonde på grund af den lave genfinding af lægemidlet ved denne dosis. 
It is not recommended to administer a dose of 0.5 ml or less with nasogastric, gastrostomy or nasojejunal tubes, given the low drug recovery in dosing.
I sådanne tilfælde kan hyppigere dosering resultere i et lavere PAA-plasmaniveau og en lavere PAA:PAGN-ratio. 
In such cases, increasing the dosing frequency may result in a lower plasma PAA level and PAA to PAGN ratio.
In vitro studier til evaluering af den procentvise genfinding af den samlede dosis leveret gennem en nasogastrisk, nasojejunal eller gastrostomisonde påviste, at procentdelen af dosen genvundet var >99 % for doser >1 ml og 70 % for en dosis på 0,5 ml. 
In vitro studies evaluating the percent recovery of total dose delivered with nasogastric or gastrostomy tubes demonstrated the percent of dose recovered was >99% for doses > 1 ml and 70% for a 0.5 ml dose.
Almindelig Træthed, perifert ødem Ikke almindelig Sult, pyreksi 
Fatigue, oedema peripheral Uncommon Hunger, Pyrexia
Hypofagi 
Hypophagia
Efter administration af 4 ml, 6 ml og 9 ml 3 gange dagligt i 3 dage til raske forsøgspersoner var forholdet mellem gennemsnitlig AUC0-23t af PAA og PAGN hhv. 1, 1,25 og 1,6. 
In healthy subjects, after administration of 4 ml, 6 ml, and 9 ml 3 times daily for 3 days, the ratio of mean AUC0-23h of PAA to PAGN was 1, 1.25, and 1.6, respectively.
Måling af PAA og PAGN i plasma kan derfor være nyttig i forbindelse med dosisbestemmelse. 
Therefore, measurement of plasma PAA and PAGN levels may be useful to guide dosing.
I in vitro studier aftog den specifikke aktivitet af lipaser, der hydrolyserer glycerolphenylbutyrat, i følgende rækkefølge: pancreas-triglyceridlipase, carboxylester-lipase, og pancreaslipase-relateret protein 2. 
In in vitro studies, the specific activity of lipases for glycerol phenylbutyrate was seen in the following decreasing order: pancreatic triglyceride lipase, carboxyl ester lipase, and pancreatic lipase-related protein 2.
Præparatet indeholder ikke hjælpestoffer. 
The product contains no excipients.
Bivirkninger rapporteret hyppigere hos pædiatriske end voksne patienter ved langvarig behandling med glycerolphenylbutyrat inkluderede øvre abdominalsmerter (3 ud af 49 børn [6,1 %] og 1 ud af 51 voksne [2,0 %]) og forhøjet anion-gap (2 ud af 49 børn [4,1 %] og 0 ud af 51 voksne [0 %]). 
Adverse reactions reported in more paediatric than adult patients during long-term treatment with glycerol phenylbutyrate included upper abdominal pain (3 of 49 paediatric [6.1%] versus 1 of 51 adults [2.0%] and increased anion gap (2 of 49 paediatric [4.1%] versus 0 of 51 adults [0%].
Efter dagens sidste dosis skal den orale sprøjte kasseres. 
After the last dose of the day, the oral syringe should be discarded.
PBA dannet fra glycerolphenylbutyrat omdannes yderligere til PAA ved β-oxidation. 
PBA derived from glycerol phenylbutyrate is further converted by β-oxidation to PAA.
Lave niveauer af eller manglende pancreasenzymer eller tarmsygdom, der medfører malabsorption af fedt, kan resultere i reduceret eller manglende hydrolyse af glycerolphenylbutyrat og/eller absorption af phenylbutyrat og i reduceret kontrol med ammoniak i plasma. 
Low or absent pancreatic enzymes or intestinal disease resulting in fat malabsorption may result in reduced or absent digestion of glycerol phenylbutyrate and/or absorption of phenylbutyrate and reduced control of plasma ammonia.
Herfordshire 
Herefordshire
Glycerolphenylbutyrat er et kvælstofbindende lægemiddel. 
Glycerol phenylbutyrate is a nitrogen-binding medicinal product.
Forstoppelse, flatulens, gastroøsofageal reflukssygdom 
Constipation, Flatulence, Gastrooesophageal reflux disease
Studie med børn under 2 måneder 
Study in Children Less Than 2 Months of Age
4-ugers, non-inferioritet, blindet overkrydsningsstudie med aktiv kontrol (studie 1) Et randomiseret, dobbeltblindt, aktivt kontrolleret non-inferioritetsstudie (studie 1) sammenlignede ækvivalente doser af glycerolphenylbutyrat og natriumphenylbutyrat ved at evaluere det venøse ammoniakniveau i 24 timer hos patienter med UCD'er, som var blevet behandlet med natriumphenylbutyrat inden inklusion med henblik på regulering af deres UCD. 
Active-Controlled, 4-Week, Noninferiority, Blinded Crossover Study (Study 1) A randomised, double-blind, active-controlled, crossover, noninferiority study (Study 1) compared equivalent doses of glycerol phenylbutyrate to sodium phenylbutyrate by evaluating 24-hour venous ammonia levels in patients with UCDs who had been on sodium phenylbutyrate prior to enrolment for control of their UCD.
5.1 og 5.2 for oplysninger vedrørende farmakodynamiske og farmakokinetiske egenskaber hos denne aldersgruppe. 
For data regarding pharmacodynamic and pharmacokinetic properties in this age group, see sections 5.1 and 5.2.
• hvis du har problemer med bugspytkirtlen, maven eller tarmene, da disse organer er ansvarlige for absorption af glycerolphenylbutyrat. 
• if you have problems with your pancreas, stomach or gut (‘intestines') - these organs are responsible for absorption of glycerol phenylbutyrate into the body.
Glycerolphenylbutyrats indvirkning på CYP2C9 og potentialet for interaktion med celecoxib er blevet undersøgt hos mennesker uden noget bevis for interaktion. 
The effects of glycerol phenylbutyrate on cytochrome P450 (CYP) 2C9 isoenzyme and potential for interaction with celecoxib has been studied in humans with no evidence of an interaction observed.
Du skal følge en særlig proteinfattig kostplan under behandling med glycerolphenylbutyrat. 
You must follow a special low protein diet during treatment with glycerol phenylbutyrate.
• sultfornemmelse, vægttab eller vægtstigning 
• feeling hungry, weight loss or weight gain
Forberedelse til administration gennem nasogastrisk sonde eller gastrostomisonde: In vitro undersøgelser til evaluering af den procentvise genfinding af den samlede dosis givet gennem en nasogastrisk, nasojejunal eller gastrostomisonde påviste, at dosis genfundet var > 99 % for doser > 1 ml og 70 % for en dosis på 0,5 ml. 
Preparation for nasogastric tube or gastrostomy tube administration: In vitro studies evaluating the percent recovery of total dose delivered with nasogastric, nasojejunal or gastrostomy tubes demonstrated the percent of dose recovered was > 99% for doses > 1 ml and 70% for a 0.5 ml dose.
Givet at ca. 47 % af kvælstoffet i kosten udskilles som overskud, og at ca. 70 % af en administreret dosis af 4-phenylbutansyre (PBA) vil blive udskilt som phenylacetylglutamin i urinen (U-PAGN), er en estimeret begyndelsesdosis af glycerolphenylbutyrat per døgn 0,6 ml pr. gram indtaget protein i kosten pr. døgn, idet det antages, at alt restkvælstof omdannes af glycerolphenylbutyrat og udskilles som phenylacetylglutamin (PAGN). 
Given that approximately 47% of dietary nitrogen is excreted as waste and approximately 70% of an administered 4phenylbutyric acid (PBA) dose will be converted to urinary phenylacetylglutamine (U-PAGN), an initial estimated glycerol phenylbutyrate dose for a 24-hour period is 0.6 ml glycerol phenylbutyrate per gram of dietary protein ingested per 24 hour period assuming all the waste nitrogen is covered by glycerol phenylbutyrate and excreted as phenylacetylglutamine (PAGN).
Det skal besluttes, om amning eller behandling med glycerolphenylbutyrat skal ophøre, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen. 
A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from glycerol phenylbutyrate therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
• Samlet daglig dosis RAVICTI (ml) = samlet daglig dosis natriumphenylbutyrat-tabletter (g) x 
• Total daily dosage of RAVICTI (ml) = total daily dosage of sodium phenylbutyrate tablets (g) x
Efter administration af en enkelt dosis glycerolphenylbutyrat havde 15 ud af 22 deltagere en kvantificerbar PBA-plasmakoncentration i den første prøve udtaget efter dosering (0,25 time). 
Upon singledose administration of glycerol phenylbutyrate, plasma concentrations of PBA were quantifiable in 15 of 22 participants at the first sample time post dose (0.25 h).
En plasma-PAA:PAGN-ratio på over 2,5 kan indikere mætning af kapaciteten til at omdanne PAA til PAGN, og det kan være nødvendigt at reducere dosis og/eller øge doseringshyppigheden. 
A plasma PAA to PAGN ratio exceeding 2.5 may indicate saturation of PAA to PAGN conversion capacity and the need for reduced dosing and/or increased frequency of dosing.
RAVICTI skal anvendes i kombination med proteinrestriktion i kosten og i visse tilfælde med kosttilskud (f.eks. essentielle aminosyrer, arginin, citrullin, proteinfri kalorietilskud). 
RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements).
Hvis det er nødvendigt at administrere en dosis på 0,5 ml eller mindre via en nasogastrisk, nasojenunal eller gastrostomisonde, skal den lave genfinding af lægemiddel tages i betragtning ved fastlæggelse af dosis. 
If there is a need to administer a dose of 0.5 ml or less with such nasogastric, gastrostomy or nasojejunal tubes, consideration should be given to the low drug recovery in dosing.
En ny lukbar adapter skal anvendes, når en ny flaske åbnes. 
A new reclosable bottle cap adapter should be used when a new bottle is opened.
UCD'erne inkluderer defekter i carbamoylfosfatsyntetase I (CPS), ornithintranscarbamylase (OTC), argininoravsyre-syntetase (ASS), argininoravsyrelyase (ASL), arginase I (ARG), og ornithin-translokase-mangel hyperammoniæmihyperornithiniæmi homocitrullinuri-syndrom (HHH). 
The UCDs include deficiencies of carbamoyl phosphate synthetase I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH).
Dosisjustering baseret på phenylacetat og phenylacetylglutamin i plasma Opkastning, kvalme, hovedpine, døsighed, forvirring eller søvnighed ved fravær af et højt ammoniakniveau eller interkurrent sygdom kan være tegn på phenyleddikesyre- (PAA) toksicitet (se pkt. 
Adjustment based on plasma phenylacetate and phenylacetylglutamine Symptoms of vomiting, nausea, headache, somnolence, confusion, or sleepiness in the absence of high ammonia or intercurrent illness may be signs of phenylacetic acid (PAA) toxicity (see section 4.4, PAA toxicity).
• tests viser højere eller lavere kalium i blodet 
• tests show higher or lower potassium in your blood
Der er et muligt potentiale for interaktion mellem glycerolphenylbutyrat som CYP3A4induktor og lægemidler, som hovedsagligt metaboliseres af CYP3A4. 
The potential for interaction of glycerol phenylbutyrate as a CYP3A4 inducer and those products predominantly metabolised by the CYP3A4 pathway is possible.
Probenecid kan hæmme den renale udskillelse af glycerolphenylbutyrats metabolitter, herunder PAGN. 
Probenecid Probenecid may inhibit the renal excretion of metabolites of glycerol phenylbutyrate including PAGN.
Forekomsten af følgende tumorer var også øget hos hunrotter: adenom, karcinom og kombineret adenom eller karcinom i tyroid follikelcelle, kombineret adenom eller karcinom i binyrebarken, cervikalt neurinom, stromale polypper og kombineret polyp eller sarkom i livmoderens endometrie. 
The incidence of the following tumours was also increased in female rats: thyroid follicular cell adenoma, carcinoma and combined adenoma or carcinoma, adrenal cortical combined adenoma or carcinoma, cervical schwannoma, uterine endometrial stromal polyp, and combined polyp or sarcoma.
De gennemsnitlige maksimale koncentrationer (Cmax) af PBA, PAA og PAGN var hhv. 37,0 mikrogram/ml, 14,9 mikrogram/ml og 30,2 mikrogram/l. 
Mean maximum concentration (Cmax) for PBA, PAA, and PAGN was 37.0 micrograms/ml, 14.9 micrograms/ml, and 30.2 micrograms/ml, respectively.
Hos raske, fastende voksne forsøgspersoner, som fik en enkelt oral dosis på 2,9 ml/m2 glycerolphenylbutyrat, forekom spidsniveauer af PBA, PAA, og PAGN i plasma efter hhv. 2 timer, 4 timer og 4 timer. 
In healthy, fasting adult subjects receiving a single oral dose of 2.9 ml/m2 of glycerol phenylbutyrate, peak plasma levels of PBA, PAA, and PAGN occurred at 2 h, 4 h, and 4 h, respectively.
RAVICTI 1,1 g/ml oral væske Glycerolphenylbutyrat 
RAVICTI 1.1 g/ml oral liquid Glycerol phenylbutyrate
Farmakokinetikken af glycerolphenylbutyrat er ikke blevet undersøgt hos patienter med nedsat nyrefunktion, herunder patienter med nyresygdom i slutstadiet (end-stage renal disease, ESRD) eller patienter i hæmodialyse. 
The pharmacokinetics of glycerol phenylbutyrate in patients with impaired renal function, including those with end-stage renal disease (ESRD) or those on haemodialysis, have not been studied.
I et yderligere langtids- (24 måneder), ukontrolleret, åbent klinisk studie blev RAVICTIs sikkerhed evalueret hos 16 UCD-patienter under 2 måneder og hos 10 pædiatriske patienter med UCD'er i alderen fra 2 måneder til under 2 år. 
In an additional long term (24 month), uncontrolled, open-label clinical study the safety of RAVICTI has been evaluated in 16 UCD patients less than 2 months of age and 10 paediatric patients with UCDs aged 2 months to less than 2 years.
• hævede led, muskelsammentrækninger, smerter i hænder og fødder, hælsmerter 
• joint swelling, muscle spasms, pain in the hands and feet, heel pain
RAVICTI 1,1 g/ml oral væske 
RAVICTI 1.1 g/ml oral liquid
Dosisjustering baseret på phenylacetylglutamin i urinen U-PAGN-målinger kan anvendes som vejledning ved dosisjustering af glycerolphenylbutyrat og til at bedømme komplians. 
Adjustment based on urinary phenylacetylglutamine U-PAGN measurements may be used to help guide glycerol phenylbutyrate dose adjustment and assess compliance.
• virusinfektion i tarmene 
• viral infection in the gut
Hvis noget af ovenstående gælder for dig (eller hvis du er i tvivl), skal du spørge lægen eller apotekspersonalet, før du tager RAVICTI. 
If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking RAVICTI.
Ammoniakniveauet skal monitoreres tæt, når glycerolphenylbutyrat-dosis ændres. 
Ammonia levels must be monitored closely when changing the dose of glycerol phenylbutyrate.
• stikkende og prikkende fornemmelse, udpræget rastløshed, besvær med at vågne, døsighed, talebesvær, forvirret eller deprimeret tilstand 
• feeling of pins and needles, feeling very restless, difficulty in waking up, feeling drowsy, problems with speech, feeling confused, depressed
Yderligere bivirkninger hos børn under 2 måneder 
Additional side effects in children less than 2 months of age
Begyndelsesdosis til patienter, som skifter fra natriumphenylbutyrat til RAVICTI: 
Initial dosage in patients switching from sodium phenylbutyrate to RAVICTI:
Hos voksne UCD-patienter, som fik flere doser glycerolphenylbutyrat, optrådte maksimale steady state plasmakoncentrationer (Cmaxss) af PBA, PAA og PAGN hhv. 8 timer, 12 timer og 10 timer efter dagens første dosis. 
In adult UCD patients receiving multiple doses of glycerol phenylbutyrate, maximum plasma concentrations at steady state (Cmaxss) of PBA, PAA, and PAGN occurred at 8 h, 12 h, and 10 h, respectively, after the first dose in the day.
Yderligere bivirkninger er blevet evalueret i et klinisk studie, der inkluderede 16 UCD-patienter under 2 måneder. 
Additional adverse reactions have been evaluated in a clinical study including 16 UCD patients less than 2 months of age.
Monitorer ammoniakniveauet nøje, når kortikosteroider og glycerolphenylbutyrat anvendes samtidig. 
Monitor ammonia levels closely when corticosteroids and glycerol phenylbutyrate are used concomitantly.
I alt 51 voksne patienter med defekter i CPS, OTC, ASS, ASL, ARG og HHH blev inkluderet i forsøget, og alle med undtagelse af 6 var blevet omstillet fra natriumphenylbutyrat til ækvivalente doser glycerolphenylbutyrat. 
A total of 51 adult patients involving deficiencies of CPS, OTC, ASS, ASL, ARG, and HHH were enrolled in the study and all but 6 had been converted from sodium phenylbutyrate to equivalent doses of glycerol phenylbutyrate.
Brug af anden medicin sammen med RAVICTI 
Other medicines and RAVICTI
I alt 16 pædiatriske patienter med UCD'er i alderen under 2 måneder deltog i et langtids(24 måneder), ukontrolleret, åbent studie, hvor 10 patienter konverterede fra natriumphenylbutyrat til RAVICTI. 
A total of 16 paediatric patients with UCDs aged less than 2 months participated in a long-term (24 months), uncontrolled, open-label study, of which 10 patients converted from sodium phenylbutyrate to RAVICTI.
Hvis noget af ovenstående gælder for dig (eller hvis du er i tvivl), skal du spørge lægen, før du tager RAVICTI. 
If any of the above apply to you (or you are not sure), talk to your doctor before taking RAVICTI.
Ikke almindelig: kan påvirke op til 1 ud af 100 personer mundtørhed, ændret smagssans 
Uncommon: may affect up to 1 in 100 people
Den gennemsnitlige eksponering var 10 måneder (interval 2-20 måneder) og den gennemsnitlige eksponering hos patienter i alderen 2 måneder til under 2 år var 9 måneder (interval 0,2-20,3 måneder). 
The median exposure was 10 months (range 2 to 20 months) and median exposure in the 2 months to less than 2 years of age was 9 months (range 0.2 to 20.3 months).Adverse drug reactions (ADR) are summarized below.
Ikke almindelig Ventrikulær arytmi 
Uncommon Ventricular arrhythmia
Flasken er pakket sammen med en genlukkelig lågadapter. 
The bottle is packed with a reclosable bottle cap adapter.
• 7 ml/m2/dag (8 g/m2/dag) hos patienter med BSA ≥ 1,3 m2 
• 7 ml/m2/day (8 g/m2/day) in patients with a BSA ≥ 1.3 m2
Vend flasken på hovedet med den orale sprøjte siddende i. 
Turn the bottle upside down with the oral syringe still inserted.
Synk væsken fra den orale sprøjte eller fastgør sprøjten til en gastrostomisonde eller nasogastrisk sonde. 
Swallow the liquid from the oral syringe or attach the oral syringe to a gastrostomy or nasogastric tube.
RAVICTI er indiceret som tillægsbehandling med henblik på kronisk behandling af patienter med urinstofcyklus-defekter (UCD'er), herunder defekter i carbamylfosfat-syntetase I (CPS), ornithintranscarbamylase (OTC), argininoravsyre-syntetase (ASS), argininoravsyrelyase (ASL), arginase I (ARG) og ornithin-translokase-mangel hyperornithinæmi-hyperammoniæmi homocitrullinuri-syndrom (HHH), som ikke alene kan behandles ved begrænsning af protein i kosten og/eller tilskud af aminosyrer. 
RAVICTI is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate synthetase I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.
• oralt (gennem munden) 
• by mouth
Glycerolphenylbutyrat bør ikke anvendes under graviditet og til kvinder i den fertile alder, som ikke anvender sikker kontraception. 
Glycerol phenylbutyrate is not recommended during pregnancy and in women of childbearing potential not using contraception.
Den samme adapter kan bruges, indtil flasken er tom. 
The same reclosable bottle cap adapter can be used until a bottle is empty.